Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avricore Health Inc V.AVCR

Alternate Symbol(s):  AVCRF

Avricore Health Inc. is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. The Company is involved in the business of health data and point-of-care technologies (POCT). HealthTab, its flagship offering, is a turnkey point-of-care testing solution that combines point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). The HealthTab also has capabilities for bacterial and viral tests, such as strep and COVID-19. The HealthTab platform transforms pharmacies into community point-of-care diagnostic centers.


TSXV:AVCR - Post by User

Bullboard Posts
Comment by CQCmasteron Mar 30, 2015 8:30pm
274 Views
Post# 23579366

RE:MY SOURCE....

RE:MY SOURCE....
mumu55 wrote: https://www.pharmacychoice.com/news/article.cfm?Article_ID=1348358

SORRY GUYS....




Sorry about what? First of all this is old news, from 2 weeks ago. Second, that's great news if you interpret it right. The email that Jason posted earlier today is basically the same information that was written by our CEO back on March 12th with fries on the side. As stated, the main focus here is to expand their portfolio with more products. Bigger inventory leads to more commercial interest and revenue in the end. However, in order to do that, they would need cash in hand. We gonna have to wait for some revenue. Small steps = small victories which will manifest into big accomplishments. I for one, think that we're moving in the right direction without any hiccups. To me it looks like that everyone here is making decisions based on other peoples opinions and the fact this is a venture stock. You know, for a venture company, I think we're doing pretty damn good. All the NRs are true to their word. Lastly, you guys can shoot me if this doesn't happen, but what I expect in April is more drugs to be approved by health Canada. Hoping for more popular molecules because out of those 30, only a few make the "top seller" list. Though the more, the better.
Bullboard Posts